Search results
Xeltis sets crosshairs on US pivotal trial for aXess after IDE green light
Medical Device Network via Yahoo Finance· 6 days agoThe US Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) to...
Japan has an excess sushi problem. These food waste activists put it in numbers
BBC News· 5 days agoRiko Morinaga, a recent high school graduate in Tokyo, normally spends her weekend nights hanging...
Microsoft Visual Studio 2010 Ultimate for Windows
CNET· 3 days agoMicrosoft Visual Studio 2010 Ultimate is a powerful integrated development environment (IDE) released in 2010. It provides a comprehensive set of tools for creating, deploying ...
North set for all star game
FOX 56 WOLF TV· 2 days agoSouth Williamsport had fantastic football season so when the North team takes the field for the district 4 all star game Friday 5 members of that team...
Gateway - The Root
The Root· 5 days agoBlock Club Chicago recently broke open a story that brings to bear many of the seediest issues perpetuating inequity in the notoriously segregated city and the country it belongs to: greed, ...
Will Filing Taxes Jointly Save Money?
The Wall Street Journal· 4 days agoFiling jointly tends to net couples the most significant tax savings since they receive the highest standard deduction—not to mention additional tax...
Hosfelt Gallery opens Rina Banerjee's fourth solo exhibition with the gallery
Art Daily· 6 days agoBorn in Kolkata and based in New York, Rina Banerjee creates shamanistic sculptures and vibrantly sensuous paintings-exploring the complexities of ide
Avinger Announces Closing of up to $24 Million Public Offering
Digital Journal· 5 days agoH.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The aggregate gross proceeds to the Company from the offering were approximately $6 million before deducting the ...
No special session: Gordon says Wyoming’s ‘well-equipped’ to fight feds on coal
Wyoming Tribune-Eagle· 2 days agoSo long as it’s up to Gov. Mark Gordon, a special session of the Wyoming Legislature to address the...
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel...
Morningstar· 3 days agoALPHA3 Trial Has the Potential to Position Cema-cel as Part of First Line (1L) Treatment for LBCL to Improve Cure RatesFirst Prospective Trial to Incorporate the Foresight Diagnostics’s Investigational CLARITY™ Test to Identify Patients with LBCL Who
